Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | CASP1 | P29466 | 1/20 | 0.76 |
| ▸ | CASP7 | P55210 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317424 | 1.00 | GFER (1.00) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL6683286 | 0.98 | GFER (0.97) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL4972251 | 0.97 | GFER (0.94) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL14635033 | 0.90 | GFER (0.81) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL150478 | 0.86 | ALOX15 (1.00) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL4586298 | 0.86 | GFER (0.76) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL30317358 | 0.85 | GFER (0.74) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL6624747 | 0.82 | GFER (0.70) | GFERALOX15MAPK1HSD17B10CASP1 | |
| SCHEMBL6683973 | 0.81 | GFER (0.68) | GFERALOX15MAPK1HSD17B10CASP1 | |
| Hydrochloric Acid SCHEMBL6497903 | 0.80 | GFER (0.66) | GFERALOX15MAPK1HSD17B10CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | claimed |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2009-07-02 | — | — | US | disclosed |
| EP-2049493-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | Cadila Healthcare Limited (IN) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008059513-A2 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CADILA HEALTHCARE LIMITED (IN) | 2008-05-22 | — | — | WO | disclosed |
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CYTOVIA INC. (CA) | 2008-04-24 | — | — | US | disclosed |
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| US-4057640-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-11-08 | — | — | US | disclosed |
| US-4057640-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-11-08 | — | — | US | disclosed |
| US-3956295-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096848-A1 | N-(2-(1H-Pyrazol-1-yl)-phenyl)-9H-fluorene-1-carboxamide for example; treating proliferative diseases such as cancer, viral diseases, inflammatory bowel disease, rheumatoid arthritis, psoriasis; combination therapy with other known anticancer drugs | CASP1, CASP9, CASP14 | GFER 3670/4885ALOX15 2001/4885MAPK1 2045/4885 |
| US-20090171091-A1 | COMPOUNDS SUITABLE AS MODULATORS OF HDL | CETP, APOB, HDLBP | GFER 4246/4885ALOX15 1692/4885MAPK1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.